SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

KMDA

Kamada Ltd.
BULLISH
Impact 6/10
Horizonweeks Processed7d 17h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The raised guidance and strong cash generation support continued organic growth. Watch for the January 2027 detailed guidance and any M&A announcements that could further accelerate growth.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

KMDA drug pipeline →

CYTOGAM

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already FDA-approved and commercially marketed
Next catalyst
None dated

What to watchCYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$7.71
T+0 close · Nov 9, 2026 · via day close
Latest settled
+5.19%
T+5 · $8.11
Vs SPY
+6.88%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $7.71entry
  2. T+1 · 7d ago +5.06%α +5.43% · $8.10
  3. T+5 · 17h ago +5.19%α +6.88% · $8.11
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kamada reported Q3 2026 revenue of $52.0M (+11% YoY) and EPS of $0.14, beating the $0.13 consensus. The company raised its full-year 2026 guidance to $205M-$208M revenue and $52M-$54M adjusted EBITDA, citing strong demand for KEDRAB and other plasma-derived products.

Key Financial Metrics

EPS
$0.14
est $0.13 · +7.7%
Revenue
$52.0M
+10.7% YoY
Rating
beat
Guidance
$205M-$208M
raised
Free Cash Flow
$16.3M
Gross Margin
44.85%

Key Facts

  • Q3 2026 revenue $52.0M, up 11% YoY from $47.0M
  • Q3 2026 GAAP diluted EPS $0.14, up 56% from $0.09 YoY
  • Q3 2026 adjusted EBITDA $15.2M, up 30% YoY, margin 29%
  • Q3 2026 net income $8.0M, up 51% YoY
  • Full-year 2026 guidance raised: revenue $205M-$208M (midpoint +14% YoY), adjusted EBITDA $52M-$54M (midpoint +26% YoY)
  • Cash from operations $19.9M in Q3, up 91% YoY; cash balance $75.3M
  • Declared $0.14/share dividend (~$8.0M); total 2026 dividends $0.56/share (~$32.2M)
  • EPS of $0.14 beat consensus of $0.13 (surprise +7.7%)
  • Revenue of $52.0M vs consensus $158.6M (note: consensus appears to be for nine-month period, not Q3 alone)

Financial Impact

Q3 revenue beat consensus by ~$1.5M (based on $52.0M vs $50.5M implied quarterly run-rate from $158.6M nine-month consensus); guidance raised by $4M at midpoint for revenue and $1.5M for adjusted EBITDA

revenueepsadjusted ebitdaoperating cash flow

Segment Breakdown

SegmentRevenueGrowth
Proprietary products$44.2M+11.8%
Distribution$7.8M+4.8%

Risk Factors

  • Geopolitical risks from Middle East conflicts and potential tariffs
  • Dependence on KEDRAB and other plasma-derived products for growth
  • Execution risk on biosimilar portfolio expansion and plasma collection ramp-up

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398271

Track record

25 reports on KMDA

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 No price data
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Viewing Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
  4. Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  5. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  6. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  7. Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
  8. Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
  9. Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
  10. Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026